ADVANCES IN NEPHROLOGY

The Endocrine Giants of Chronic Kidney Disease

Sourabh Sharma[1], Neha Sharma[2], Sanjay Kalra[3]

Abstract

Chronic Kidney Disease (CKD) is increasingly being recognized as an endo-metabolic disorder in which a cascade of hormonal and electrolyte imbalances impacts the morbidity and mortality. We propose six "endocrine giants" of CKD- anaemia, secondary hyperparathyroidism, hypovitaminosis D, hypogonadism, hyperkalaemia, and hyponatraemia- each exerting a detrimental effect on cardiovascular, skeletal, metabolic, and neurological health. Their early recognition and prompt management can attenuate downstream cardiometabolic sequelae. This "endocrine giants" framework provides an integrative approach to managing CKD as a multisystem endocrine disorder and offers practical direction for holistic nephrology care.

Keywords: Chronic kidney disease, Anaemia, Secondary hyperparathyroidism, Hypovitaminosis D, Hyperkalaemia, Hyponatraemia, Hypogonadism

DOI: https://doi.org/10.47391/JPMA.26-13

The Six Endocrine Giants of CKD

The six endocrine giants include the hormonal and homeostatic axes disrupted by kidney dysfunction.[1] (Table). These giants are interlinked though various pathways and together define the endocrine signature of CKD. Anaemia is the classical giant and most emblematic endocrine manifestation of CKD. Anaemia in CKD is anaemia of chronic disease which results from reduced erythropoietin (EPO) synthesis, functional iron deficiency, inflammation, and shortened lifespan of red blood cells.[2] Secondary hyperparathyroidism and uraemic toxins further suppress erythropoiesis.[3] Anaemia further increases the morbidity through left ventricular hypertrophy, cognitive dysfunction, fatigue, and worsened quality of life. Correction with iron and erythropoiesis-stimulating agents, coupled with control of CKD- mineral bone disease (CKD-MBD) and inflammation, improves outcomes and survival.[3,4]

With progressive nephron loss, phosphate retention, reduced calcitriol synthesis, and hypocalcaemia stimulate parathormone (PTH) secretion. Secondary hyperparathyroidism (HPT) becomes a major driver of bone turnover abnormalities, vascular calcification, anaemia, and even immune dysfunction.[5]

Targetted management using phosphate binders, vitamin D analogues, calcimimetics, and parathyroidectomy where indicated can substantially improve morbidity and mortality. The PTH–vitamin D–FGF23 axis represents the most established endocrine dysregulation in CKD.[5,6] On the other hand, the vitamin D deficiency in CKD results mainly from reduced sunlight exposure, urinary loss of binding proteins, and loss of renal 1α-hydroxylase activity. Both nutritional (25-hydroxy) and active (1,25-dihydroxy) forms are usually deficient. Hypovitaminosis D exacerbates secondary HPT, bone fragility, sarcopenia, immune dysfunction, and cardiovascular risk. Correcting vitamin D status has pleotropic benefits beyond mineral metabolism-including modulation of inflammation and insulin

[1]Department of Nephrology, Vardhman Mahavir Medical College and Safdarjung Hospital, New Delhi, India; [2]Department of Pathology, Vardhman Mahavir Medical College and Safdarjung Hospital, New Delhi, India; [3]Department of Endocrinology, Bharti Hospital, Karnal, India; University Center for Research & Development, Chandigarh University, Mohali, India.
Correspondence: Sanjay Kalra. e-mail: brideknl@gmail.com
ORCID ID: 0000-0003-1308-121X

Table-1: The Six Endocrine Giants of CKD.

Endocrine Disturbance	Key Mechanism	Major Consequences	Targeted Management
Anaemia	↓ EPO, inflammation, iron deficiency	Fatigue, LVH, mortality	Iron, ESA, CKD-MBD
Secondary HPT	↑ Phosphate, ↓ Calcitriol, ↓ Ca^{2+}	Bone disease, vascular calcification	Phosphate binders, Vit D, calcimimetics
Hypovitaminosis D	↓ Sunlight exposure, ↓ 1α-hydroxylase, urinary loss	Bone fragility, immune dysfunction	Vit D repletion / analogues
Hypogonadism	↓ Gonadal axis activity	Muscle loss, anaemia, infertility	Hormone therapy (Individualise)
Hyperkalaemia	↓ Renal excretion, RAASi use	Arrhythmia, therapy limitation	Potassium binders, dietary control
Hyponatraemia	Impaired water excretion, ↑ ADH	Falls, cognitive decline, mortality	Fluid restriction, treat cause

EPO- Erythropoietin, ESA- Erythropoiesis-stimulating agent, CKD-MBD- chronic kidney disease–mineral and bone disorder, Vit D- Vitamin D, RAASi- Renin-angiotensin-aldosterone system inhibitor, ADH- Anti diuretic hormone, HPT- Hyperparathyroidism, LVH- Left ventricular hypertrophy, Ca2±Calcium.

resistance.[7]

Sex hormone deficiency is highly prevalent yet underdiagnosed in CKD. Uraemic toxins, metabolic acidosis, hyperprolactinaemia, and chronic inflammation disrupt the hypothalamic–pituitary–gonadal axis, leading to reduced testosterone and oestrogen levels.8 Clinically, hypogonadism manifests as fatigue, infertility, decreased libido, osteoporosis, anaemia, and muscle wasting. Restoring hormonal balance (with appropriate caution) can improve physical and psychological well-being, and may synergize with other interventions such as anaemia correction.[8,9]

Hyperkalaemia is a sentinel marker of advanced tubular dysfunction and impaired aldosterone response. It often arises from reduced distal sodium delivery, metabolic acidosis, or use of renin–angiotensin–aldosterone system inhibitors (RAASi). It poses a direct risk of arrhythmia and sudden cardiac death while paradoxically limiting the use of cardioprotective therapies. The emergence of newer potassium binders provides renewed opportunity to safely maintain RAASi and SGLT2i therapy- transforming hyperkalaemia from a prohibitive barrier to a manageable endocrine- electrolyte disorder.[10]

Hyponatraemia in CKD is multifactorial- impaired free water clearance, inappropriate antidiuretic hormone (ADH) activity, and dilutional states.[11] Chronic mild hyponatraemia, once thought benign, is now linked to gait disturbance, falls, cognitive decline, and mortality. Its management requires addressing water intake, diuretic use, and underlying causes while avoiding rapid correction.[12] Recognizing hyponatraemia as a "neuroendocrine reflection" of CKD emphasizes that water handling is as much an endocrine process as it is a renal one.

Interaction among the Giants

The six endocrine giants of CKD exist not as isolated abnormalities but as an intricately connected network of metabolic and hormonal perturbations. Anaemia, the hallmark endocrine manifestation of CKD, is both influenced by and contributory to several of these disturbances. Elevated PTH levels in secondary HPT can suppress erythropoiesis and cause bone marrow fibrosis, thereby worsening anaemia, while vitamin D deficiency further impairs erythropoietin responsiveness and promotes inflammatory cytokine release. Hypogonadism, through reduced androgen and oestrogen levels, diminishes erythropoietic drive and contributes to sarcopenia and bone fragility, linking it functionally to both anaemia and CKD-MBD axis.[4-7]

Electrolyte disturbances such as hyperkalaemia and hyponatraemia reflect the progressive tubular and hormonal dysfunction characteristic of CKD. Hyperkalaemia arises from impaired renal excretion and reduced aldosterone responsiveness, conditions that often coexist with hyponatraemia driven by inappropriate vasopressin activity and impaired free water clearance. Together, they represent the loss of renal endocrine control over key homeostatic mechanisms- aldosterone and ADH signalling. These derangements not only mirror the structural decline of nephrons but also amplify cardiac and neurological vulnerability, increasing the risk of arrhythmias, hypotension, and cognitive dysfunction.[10-12]

The interplay among these giants forms a vicious cycle: chronic inflammation and malnutrition aggravate anaemia and hypoalbuminaemia, which in turn enhance hormonal dysregulation and electrolyte imbalance. Vitamin D deficiency and HPT exacerbate vascular calcification and cardiac remodelling, which are further worsened by anaemia-induced hypoxia and hyperkalaemia-induced conduction defects.[5,6] Hyponatraemia, by impairing neuronal function and precipitating falls, adds a neurocognitive dimension to the frailty phenotype in CKD.[11,12] Collectively, these interactions create a complex web of metabolic interdependence that defines the systemic nature of CKD as an endocrine disorder.

Renal Endocrinology

Identifying these endocrine giants empower clinicians with a structured lens for metabolic screening in CKD. Routine monitoring of haemoglobin, PTH, calcium, phosphate, vitamin D, electrolytes, and gonadal hormones- beginning at CKD stage 3- allows early intervention before irreversible complications occur.1,2 Multimodal targetted management strategies (Table) can attenuate disease progression and improve survival. The six giants model encourages renal endocrinology within nephrology practice- addressing upstream hormonal and homeostatic disruptions rather than downstream sequelae.

Conclusion

The "Six Endocrine Giants of CKD" framework integrates endocrine-homeostatic disorders into a unified clinical construct. Together, they define the metabolic phenotype of CKD and shape its complications.

Their recognition reframes CKD as a state of multisystem endocrine failure rather than isolated renal insufficiency. Managing these giants proactively can delay progression, enhance quality of life, and transform outcomes in CKD care.

References

1. Zha D, Gao P, Wu X. Role of Metabolic Abnormalities During the Progression of Chronic Kidney Disease and Preventive Strategies. Int J Med Sci. 2025;22:3543-3555.
2. Sahay M, Kalra S, Bandgar T. Renal endocrinology: The new frontier. Indian J Endocrinol Metab. 2012;16:154-5.
3. Babitt JL, Lin HY. Mechanisms of anemia in CKD. J Am Soc Nephrol. 2012;23:1631-4.
4. Portolés J, Martín L, Broseta JJ, Cases A. Anemia in Chronic Kidney Disease: From Pathophysiology and Current Treatments, to Future Agents. Front Med (Lausanne). 2021; 8:642296.
5. Sharma S, Rampal S, Jaiman A, Saravanamuttu SL, Jaiman A, Kamaruzaman L, et al. Exploring musculoskeletal disorders in end-stage kidney disease: a systematic review. Med J Malaysia. 2025;80:102-107.
6. Nitta K, Nagano N, Tsuchiya K. Fibroblast growth factor 23/klotho axis in chronic kidney disease. Nephron Clin Pract. 2014;128:1-10.